At the end of 2018, major medical consulting agencies began a year-end summary analysis of the medical industry in this year and made predictions for the development of 2019. The medical industry in 2018 can be described as lively and extraordinary, the entry of social capital in different fields, the rise of artificial intelligence, medical equipment and medicine are not far behind. So, what are the development trends worth looking forward to in the medical industry in 2019?
Trend 1: 4+7 quantity procurement sees results in the third quarter of 2019
“4+7 quantity procurement†is definitely one of the hottest topics at the end of 2018. The purchase of medicines can be said to be an attempt by the National Medical Insurance Bureau to explore the experience. The volume procurement was launched in Shanghai, and the average price of the winning drugs was over 50%, which met the expected target. After the medical insurance system has mastered the new model, the localities will begin to copy. However, due to the distribution of the winning drugs, the monitoring of the use of hospitals, and the control of drug quality, it takes about half a year. Therefore, it is necessary to look at the accurate results of 2019.
Trend 2: Difficulties in drug promotion, practitioners may be unemployed
The reform of quantity procurement and medical insurance payment method is definitely a strong impact on the current marketing model, which will subvert the existing marketing model, resulting in no shortage of medical marketing in 2019. Practitioners may be unemployed in large numbers. .
It is expected that in 2019, there will be development space and opportunities for professional medical representatives. The so-called professional medical representative refers to the ability to provide doctors with more academic and career planning assistance. At the same time, with the general opening of the filing system and the reception system, the reputation of medical representatives will be positively spread by public opinion, and the image will gradually change from the beginning of 2019.
Trend 3: Small and medium-sized pharmaceutical companies and drug dealers are stagnation, small and medium-sized pharmaceutical companies and drug dealers work for the giants
On the one hand, the funds of large pharmaceutical companies and drug dealers are tense; another reason is that the quality assets in the market are scarce, and the valuation of small and medium-sized pharmaceutical companies and drug dealers is shrinking at this stage. Two reasons have led to a slowdown and stagnation in the pharmaceutical industry. In 2019, small and medium-sized pharmaceutical companies and drug dealers were less and less likely to be merged, and it was more common to trade unions for large pharmaceutical companies.
Trend 4: Consistency evaluation is gathered in three or increased to five
From the point of view of the national policy to encourage enterprises to actively do consistent evaluation, "collecting three" is only a phased administrative means.
With the increasing number of products with the same generic name and the same specification passed the consistency evaluation next year, this restriction should be loosened, and it is not even ruled out that it will be relaxed to “five fullâ€, thus ensuring equal competition for drugs.
In addition, the mode of purchasing competitive bidding requires more evaluation of drug participation, and stimulates pharmaceutical companies to show greater sincerity. Over time, more and more drugs have been reviewed, and the policy of “selling a number of households and prioritizing procurement and use†has reached its goal.
Trend 5: Pharmaceutical companies must pay attention to R&D and quality, and strictly control marketing
Pharmaceutical companies in the eyes of everyone are selling drugs to hospitals and pharmacies, so most pharmaceutical companies invest heavily in marketing. Due to the marketing drive, the R&D investment and marketing investment of pharmaceutical companies are hugely different, which is itself a matter of putting the cart before the horse. If pharmaceutical companies only focus on marketing and research and development, not only can they not innovate, but quality may not be guaranteed.
In fact, this is also a commonplace. Any enterprise in an industry must rely on quality products and new products to prosper. The pharmaceutical companies should also be like this. In 2019, under the impetus of volume procurement, pharmaceutical companies should focus on quality, cost control and R&D.
Trend 6: The DTP and the yard shop in 2019 is a "delicious fat"
In recent years, in order to promote the outflow of prescription drugs, DTP pharmacies and hospitals have become the "fat" of hospitals, pharmacies and pharmaceutical companies. DTP and hospitals are also an inevitable result of the development of the pharmaceutical market.
Due to the major medical ecology and the adjustment of the structure of the pharmaceutical industry that the medical reform is currently to solve, this non-mainstream edge ball will not be taken care of for the time being. Therefore, in 2019, the doctor's gray income will continue to decline for a year or even longer, and the corresponding DTP and yard stores will have more space next year.
to sum up
It is about to bid farewell to the medical industry in 2018. The medical industry in 2019 believes that it will not stop its development. After all, deepening medical reform relies on the efforts of all walks of life. What are the views on the development forecast of the industry in 2019? I hope that the experts and friends of the medical industry will make their own speeches in the message area!
Guangzhou Zhongzhinan Supply Chain Co.,Ltd. , https://www.zhongzhinanlighting.com